newsfilter
← Latest News
Business Wire·

TherapeuticsMD Announces Third Quarter 2021 Financial Results

- Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 - - ANNOVERA® TRx of 8,351, an increase of 62.7% over Q3 2020 - - Cost savings initiative to reduce SG&A by $40 million in 2022; anticipated additional savi